Luminescens^®

Chronic melanin dysregulation is challenging to treat. Luminescens® comprehensively targets hyperpigmentation with a unique formulation that promotes even skin tone and compatibility across all skin types and colours.

Australia’s active, outdoor lifestyle prediposes us to higher incidence of skin damage and accelerated skin ageing. In chronic conditions and dermatological disorders characterised by dyschromia, including post-inflammatory hyperpigmentation or melasma, melanocyte hyperactivity or dysregulation occurs when the melanocytes continue to produce more melanin than usual, even after the original stimuli – such as sun exposure, heat, hormones or inflammation – are reduced or eliminated. This sustained overproduction of melanin, due to melanocyte dysregulation, is often challenging to treat and may require ongoing interventions to manage melanin levels.

Luminescens® is a skin brightening and pigmentation solution for the face and body, developed and manufactured by CMed Aesthetics S.r.L (Pisa, Italy). The skin brightening function is carried out by specific active ingredients, assisted by a superficial peeling action that promotes epidermal renewal and permits the delivery to deeper dermal layers. It includes antioxidants and dermo-normalising agents (like glutathione); salicylic acid to increase cell turnover; melanin formation and transport blockers; and melanogenic enzyme blockers, including tranexamic acid. The formulation is compatible with all Fitzpatrick shades, including dark phototypes, and all skin types, and is suited for both oily and dry skin.

The Luminescens® Professional Kit contains two vials of Luminescens® Professional Serum (4ml each) and one Home Cream (30ml). The two vials of Serum facilitate up to four in-clinic treatments, which must be applied by a professional practitioner. The Luminescens® Home Cream is applied at the clinic immediately after the Professional Serum treatment and is supplied to the client to take home to form part of their daily home skin routine.

The Professional Serum vials may be combined with various treatment protocols, including derma blading, microneedling and electroporation, subject to practitioner qualifications. The Home Cream can also be combined with numerous modailites for general skin brightening and enzymatic suppression, to minimise melanocyte hyperactivation.

Clear benefits of Luminescens®

Luminescens® treatment system provides significant advantages for clinics and clients alike:

• Low adoption cost: Luminescens® requires minimal capital investment and has low holding costs. Training for clinic staff is provided by CMed Aesthetics ANZ at no additional expense, making it an accessible alternative to high-cost laser treatments, especially when managing recurrent pigmentation issues like melanocyte hyperactivation.
• Professional treatment starts and ends in-clinic:
  The Luminescens® in-clinic Professional Serum treatment is entirely completed at the clinic. There is no risk of adverse developments occurring outside of clinical supervision, which can be impossible to manage as soon as the patient leaves the clinic. Consequently, there is virtually no cosmetic downtime with Luminescens® treatment.
• Luminescens® Home Cream provides a cost-effective skincare solution: The Home Cream offers a non-invasive option that empowers the patient to manage melanocyte hyperactivation as needed, giving them control over their skincare routine and helping to maintain results over the long term.
• Luminescens® provides multiple mechanisms of action:
  • Supports the appearance of even skin tone.
  • Supports post-inflammatory hyper pigmentation associated with acne.
  • Antioxidant and anti-free radical action
  • Increased cell turnover and hyperpigmentation removal and suppression.

A 48-year-old Caucasian female presented with a several-year history of facial melasma, localised symmetrically on the forehead and cheeks, managed by different approaches: chemical peelings, lasers and light treatments, and topical treatments like hydroquinone and other cosmetics, with partial and transitional improvement (Figure 1). The patient was frustrated from these many unsuccessful attempts at treatment, and she did not want further invasive measures. Therefore, according to the patient’s requests and physician’s opinion, we decided to employ Luminescens® for both clinical and home treatment.

For the outpatient treatment, the application method was microneedling using 1Need Pen (Campomats), a medical device equipped with a sterile and single- use tip with nine needles able to penetrate from 0.15–2.5mm.

For each ambulatory session we applied 2ml of Luminescens® mesotherapy all over the face and performed three complete passes by 1Need Pen (1.5mm), with circle movements. We performed one outpatient treatment every 15 days for a total of four complete sessions, using overall two vials available in the Professional Kit. After the first clinic treatment, the patient received Luminescens® Home Cream (30ml) to apply once a day, in the evening, massaging until completely absorbed, for the complete treatment period.

We performed a control assessment two months from the beginning and about 15 days after the last ambulatory session and recorded a very satisfying improvement (Figure 2). The facial skin appeared light and bright, with a significant reduction of melasma hyperpigmentation over the entire face, and this was particularly apparent on the forehead and cheeks. The patient has demonstrated a very good compliance with the treatment. She reported that she had only a moderate erythema after the ambulatory sessions with no crusting or massive exfoliation.

Conclusion

Melasma remains a challenging and universally relapsing condition. To reach a more rapid and stable improvement, this often psychologically devastating disorder should be treated with a multimodality approach that incorporates photoprotective agents, antioxidant treatments, skin lighteners and exfoliants.

Luminescens® is a protocol with lightening and depigmenting activity. We obtained a very satisfactory result on resistant and recurrent melasma in a patient previously treated with laser / light, chemical peelings and different kinds of topical devices. The patient achieved a significant reduction of hyperpigmentation and a global improvement of facial skin quality in just two months of treatment, without complications or side effects.

Case report 2

By BeautyMedix, Margherita Koumbarakos, Dermal Therapist, Melbourne, Australia.

A 67-year-old female presented with significant photodamage resulting from extended unprotected sun exposure over decades of outdoor activities including windsurfing, snorkelling and sailing. The skin displays severe loss of elasticity, static wrinkles, and a rough texture due to the detrimental effects of ultraviolet (UV) radiation. Common issues include actinic keratosis, which presents as rough, scaly patches, and solar elastosis, resulting in skin thickening and yellowing from elastic tissue degeneration. Dyschromia

is prevalent, characterized by hyperpigmentation, including conditions such as melasma with brown facial patches, freckles, and age spots. Additionally, telangiectasia, or the appearance of small widened blood vessels, is evident.

Treatment over a period of eight months commenced with a series of BiORePeelCl3® treatment over six months. At month eight a Luminescens® Serum in-clinic treatment session with derma blading was conducted. The patient commenced using Luminescens® Home Cream two weeks prior to the Luminescens® in- clinic treatment.

Image 1 and 2 (daylight) show pre and post treatments. Images 3, 4 and 5 (Meicet MC88 Skin Analyser – ‘UV Spots’ images) were taken before first treatment in March 2024, after last BioRePeelCl3® treatment in September 2024 and after final treatment of Luminescens in October 2024, respectively. Note the skin tone correction in image 3, which is after only one Luminescens® Serum in-clinic treatment. Another two Luminescens® Serum treatments are scheduled; meanwhile the patient is continuing with the Home Cream as part of her daily skin regimen.

Conclusion

The patient is delighted with the results. Visible static rhytides and wrinkles are reduced, and there is a more even tone of skin on the face where Luminescens® Serum treatment was combined with derma blading conducted as part of the in- clinic treatment.

Additional Luminescens® Serum treatments are scheduled for this patient. The patient is maintaining skin brightening and tone uniformity by utilising the Luminescens® Home Cream on her face and neck as part of her daily skincare routine. AMP